Key facts
- This page summarizes Cameron Turtle's Form 3 filing for Aeglea BioTherapeutics, Inc. (SYRE).
- 0 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 30 Jun 2023, 17:14.
Cameron Turtle - 22 Jun 2023 Form 3 Insider Report for Aeglea BioTherapeutics, Inc. (SYRE)
- Reporting relationship
- Chief Operating Officer
- Issuer ticker
- SYRE
- Reported as of
- 22 Jun 2023
- Net transaction value
- $0
- SEC form
- 3
- Accepted by SEC
- 30 Jun 2023, 17:14:04 UTC
- Next SEC filing
- 27 Nov 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Jonathan Alspaugh, by power of attorney
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Cameron Turtle filed Form 3 for Aeglea BioTherapeutics, Inc. (SYRE) on 30 Jun 2023.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Official SEC source
View source filing
Ownership activity is grounded in SEC Form 3 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
AGLE
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 576,699
- Date
- 22 Jun 2023
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
AGLE
holding
Derivative
Stock Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 22 Jun 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 47,297,197
- Exercise price
- $0.3000
- Footnotes
- F2
AGLE
holding
Derivative
Series A Preferred Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 22 Jun 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 18,086,000
- Exercise price
- Footnotes
- F3, F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 4 footnotes
Footnote F1
Includes 544,565 shares of Common Stock that vest over an approximately three year period, subject to the continuing service of the Reporting Person on each vesting date.
Footnote F2
The stock option vests and becomes exercisable in 48 equal monthly installments beginning on June 22, 2023, subject to the continuing service of the Reporting Person on each vesting date.
Footnote F3
Following stockholder approval of the conversion of Series A Preferred Stock into shares of Common Stock, each share of Series A Preferred Stock will automatically convert into 1,000 shares of Common Stock, subject to certain limitations.
Footnote F4
Includes 17,186,000 shares of Common Stock that vest over an approximately three year period, subject to the continuing service of the Reporting Person on each vesting date.
SEC remarks
Exhibit 24 - Power of Attorney